MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dementia with Lewy bodies (DLB)"

  • 2023 International Congress

    Quetiapine for the treatment of psychosis in dementia with Lewy bodies: a systematic review.

    M. Giusti, PL. Silva, G. Bolner, C. Menegon, MF. Felippe, G. Herwig, A. Rossato, EG. Almeida, M. Rosa, CR. Rieder (Porto Alegre, Brazil)

    Objective: Perform a systematic review of the literature about the efficacy of quetiapine in the treatment of psychosis in patients with Lewy’s Body Dementia. Background:…
  • 2023 International Congress

    Falls in Mild Cognitive Impairment with Lewy bodies (MCI-LB).

    E. Lirani Silva, S. Waite, C. Hamilton, P. Donaghy, J. O'Brien, J. Taylor, J. Lloyd, L. Allan, M. Firbank, A. Thomas, A. Yarnall (Newcastle, United Kingdom)

    Objective: to identify clinical, physical activity and mobility measures that differentiate patients with mild cognitive impairment with Lewy bodies (MCI-LB) fallers and non-fallers from cognitively…
  • 2023 International Congress

    Clinical characteristics of patients with dementia with Lewy bodies followed in a movement disorder clinic

    AS. Jakobsson, L. Salvesen, AM. Hejl (Copenhagen, Denmark)

    Objective: To describe the clinical phenotype of the subgroup of patients with Dementia with Lewy bodies (DLB) followed in a movement disorder setting rather than…
  • 2023 International Congress

    Comparative efficacy of pharmacological cognitive treatments in Parkinson’s disease and Dementia of Lewy Bodies: systemic review & network meta-analysis

    F. Al Hajraf, S. Manohar, M. Hu (Oxford, United Kingdom)

    Objective: The aim of this study is to evaluate, compare and rank the currently available pharmacological cognitive treatments. Background: Treating cognitive impairment in Parkinson’s disease…
  • 2023 International Congress

    Keeping patients out of care facilities— clozapine rescues Parkinson’s patients with troublesome psychosis unresponsive to quetiapine and pimavanserin.

    J. Iseringhausen, G. Riboldi, K. Astudillo, S. Frucht (New York, USA)

    Objective: We describe a single-center cohort of Parkinson patients in crisis with troublesome psychosis unresponsive to quetiapine and pimavanserin, who were rescued by treatment with…
  • 2023 International Congress

    Combined GWAS of Dementia with Lewy Bodies, REM-Sleep Behavior Disorder, Parkinson’s Disease and Alzheimer’s Disease

    P. Saini, E. Yu, L. Krohn, Z. Gan-Or (Montreal, Canada)

    Objective: To identify genetic variants that are either shared between or specific for Dementia with Lewy Bodies (DLB), REM Behavior Disorder (RBD), Parkinson’s disease (PD)…
  • 2023 International Congress

    Utility of quantitative EEG during sleep as a potential biomarker of Lewy body disease progression

    E. Matar, K. Ehgoetz Martens, R. Grunstein, A. D'Rozario, S. Lewis (Sydney, Australia)

    Objective: Objective: To assess whether progression from isolated REM sleep behaviour disorder (iRBD), established Parkinson’s disease (PD) and Dementia with Lewy bodies (DLB) are accompanied…
  • 2023 International Congress

    Are patients presenting earlier in time? Secular changes in REM sleep behavior disorder

    S. Joza, A. Stefani, A. Iranzo, J. Montplaisir, B. Högl, A. Pelletier, A. Ibrahim, JF. Gagnon, R. Postuma (Montreal, Canada)

    Objective: To determine if secular changes occur in REM sleep behavior disorder (RBD). Background: RBD is the strongest clinical marker of prodromal synucleinopathy, and provides…
  • 2023 International Congress

    Myocardial sympathetic denervation biomarkers for early detection of prodromal DLB

    M. Park, J. An (Daegu, Republic of Korea)

    Objective: Because of the time course of detecting DLB symptoms and signs, DLB is poorly diagnosed and hardly differentiate from AD, especially in early stage…
  • 2023 International Congress

    Potentially inappropriate medication useage among patients newly diagnosed with dementia with Lewy bodies

    K. Wyman-Chick, E. Chrenka, M. Barrett, M. Miller, L. Sargent, J. Kuntz, H. Nguyen, A. Werner, Z. Libert, R. Rossom (St Paul, USA)

    Objective: Investigate the use of potentially inappropriate medications (PIM) among patients newly diagnosed with dementia with Lewy bodies (DLB). Background: PIM, including anticholinergics, are associated…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 20
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • An atypical and interesting feature of Parkinson´s disease
  • #24752 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • An atypical and interesting feature of Parkinson´s disease
  • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley